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Currently, intraperitoneal (IP) injection of D-luciferin is the preferred method of providing substrate for bioluminescence imaging
(BLI); however it has a failure rate of 3–10% due to accidental intestinal injection. The present study evaluates the quality of BLI
after subcutaneous (SC) injection of D-luciferin and demonstrates the effectiveness of SC injection in anatomically disparate tumor
models. Mice bearing luciferase-expressing tumors underwent BLI after SC or IP injection of D-luciferin. The average time to
maximal luminescence was 6min (range 5–9min) after SC injection and 8min (range 5–8min) after IP injection.Within 7minutes
of injection, SC and IP routes yielded similar luminescence in subcutaneous, intracranial, tongue, and lung xenograft tumormodels.
In a model of combined subcutaneous and intracranial xenografts, SC injection resulted in proportional luminescence at all sites,
confirming that preferential delivery of substrate does not occur. While tumors were occasionally not visualized with IP injection,
all tumors were visualized reliably with SC injection. Thus, SC injection of D-luciferin is a convenient and effective alternative to
IP injection for BLI in nude mice. It may be a preferable approach, particularly for tumors with weaker signals and/or when greater
precision is required.
1. Introduction
Bioluminescence is a naturally occurring phenomenon in
certain species such as the firefly resulting from oxidation of
luciferin to oxyluciferin in the presence of molecular oxygen
and adenosine triphosphate. This reaction is catalyzed by the
enzyme luciferase and results in the emission of light [1].
Bioluminescence imaging (BLI) is an in vivo optical imaging
technique that detects light emitted from firefly luciferase-
expressing cells by special charge coupled device (CCD)
camera [2]. This is an extremely valuable experimental tool
in cancer biology [3]; noninvasive whole body BLI allows
repeated, real-time, and in vivo monitoring of tumors in
experimental animal models, regardless of tumor location
[2, 4]. This technique can be used to monitor tumor growth
[5, 6], cell trafficking [7], protein-protein interactions [8],
and response to treatment, including gene therapy and
immunotherapy [9, 10]. Sensitivity of BLI is dependent
on various factors including the level of cellular luciferase
expression, implantation site of the tumor, and oxygenation
and viability of the target tissue [11].
The availability of luciferin at the site of interest is
a key element of BLI. D-luciferin can be delivered by
intraperitoneal (IP) or intravenous (IV) injection [12, 13],
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but currently IP injection is preferred because of its con-
venience. D-luciferin is absorbed through the peritoneum
and reaches luciferase-expressing cells and tissues via the
blood stream. The IP approach carries the risk of injection
of D-luciferin into the bowel, which reduces the substrate
concentrations at the target tissue resulting in a weaker
bioluminescence signal (BLS) [14, 15]. Additionally, some
body organs (e.g., pancreas and spleen) have preferential
uptake ofD-luciferin after IP injection [16].These factorsmay
result in inconsistency of luminescent signal and poor test
reproducibility; these issues are often not fully recognized
[17]. Subcutaneous (SC) injection of D-Luciferin is another
route of administration that has been successfully utilized
for BLI, for example, in a rat brain tumor model where
intensity of BLS was successfully correlated with tumor size
[5, 18].
Subcutaneous injection is straightforward and carries
little or no risk of missed injection, but it has not been
extensively evaluated. The present study assesses the utility
of SC injection of D-luciferin as an alternative route to
IP administration for BLI of xenograft tumors in nude
mice. Sequential BLI of nude mice bearing either subcuta-
neous, intracranial, lung, or tongue xenografts derived from
luciferase-expressing cells was performed. The intensity and
kinetics of the BLS were evaluated and the results after SC
or IP injection were compared. The reproducibility of the
BLS on different days was also evaluated and correlated with
tumor growth. The study demonstrates that SC injection is
an easy and effective route of administration for D-luciferin
with a rapid-onset and reproducible BLS regardless of tumor
location.
2. Materials and Methods
2.1. Cell Lines. U87 human malignant glioma cells and
A549 lung adenocarcinoma cells were obtained from ATCC
(Manassas, VA). GBM12 cells, generously provided by Dr.
C. David James, are derived from a human GBM xenograft
model system [19]. All cell lines were transfected with the
cDNA encoding firefly luciferase (pGL3 Luciferase, Promega)
and selected with G418 to permanently produce U87-Luc,
A549-Luc, and GBM12-Luc cell lines. Cells were maintained
in DMEM medium (Invitrogen, Grand Island, NY) sup-
plemented with 10% fetal bovine serum (JRH Biosciences,
Lenexa, KS) and 1% penicillin/streptomycin (Invitrogen).
OSC19-Luc head and neck squamous carcinoma cells were
kindly provided by Dr. Jeffrey Myers (MD Anderson Cancer
Center, Houston, TX) and were maintained in DMEM/F12
medium (Gibco, Grand Island, NY) supplemented with 5%
fetal bovine serum (JRH) and 1% penicillin/streptomycin
(Invitrogen).
2.2. Animals. Xenograft tumors were generated in nude
mice and allowed to grow for 7 days before the first BLI
was performed. Subsequently, mice underwent BLI at the
times specified for each experiment. The mice were han-
dled in accordance with IACUC guidelines; experiments
were approved by the institutional Committee for Animal
Research. Numbers of mice in each study are indicated in the
corresponding figure legends.
Subcutaneous Flank Tumor Model. 1 × 106 U87-Luc cells in
100 𝜇L PBS were injected subcutaneously in the dorsal side
of the upper hind limb of female nude mice using insulin
syringe.
Intracranial Tumor Model. Mice were sedated with 10mg/kg
ketamine, and a burr hole was made using a Dremel drill
approximately 2mm lateral and 2mm posterior to the inter-
section of the coronal and sagittal sutures. 1×105 GBM12-Luc
cells were injected into the brain using a Hamilton syringe at
a depth of 3mm in a volume of 5 𝜇L.
Intrathoracic Tumor Model.Mice were sedated with 10mg/kg
ketamine and 1 × 106 A549-Luc cells in 100𝜇L PBS were
injected into the right lung upper lobe through the intercostal
muscle using a Hamilton syringe.
Tongue Tumor Model. Mice were sedated with 10mg/kg
ketamine and 3 × 104 OSC19-Luc cells suspended in 30 𝜇L
of PBS were injected submucosally into the ventral aspect of
the tongue as previously described [20].
2.3. BLI Device and Setting. BLI was performed using the
IVIS-200 Imaging System (Xenogen Corporation, Berkeley,
CA). Anesthesia was induced with 2% isoflurane (Abbott
Laboratories, Chicago, IL) inhalation in a special air tight
transparent anesthesia box for 3–5min before the mice were
moved to the light-tight chamber of the CCD camera in
the imaging position. Whereas IP injections of D-luciferin
(Xenogen; 150mg/kg in 200𝜇L)were performed immediately
before anesthesia, SC injection was performed after anes-
thetizing and moving the mice in to the imaging chamber.
SC injections of D-luciferin (Xenogen; 150mg/kg in 200 𝜇L)
were performed dorsally in the midline, midway between the
head and tail. When IP and SC injection were evaluated in
the same group of mice, an interval of at least 3 h was allowed
for completewashout of the substrate. Sequential imageswere
acquired at 1min intervals (60 s exposure, no time delay)
for at least 30min. The luminescence camera was set to 60 s
exposure, medium binning, f/1, blocked excitation filter, and
open emission filter. The photographic camera was set to 2 s
exposure, medium binning, and f/8. Field of view was set to
image all mice simultaneously. Identical settings were used to
acquire each image and region of interest during the study as
previously described [21].
The luminescent area of the xenograft tumor was defined
as the region of interest (ROI) and the total signal in the ROI
(photon/sec/m2) was quantified using Living Image software
3D (version 1; Xenogen). The ROI was applied to all images
of the same sequence of each tumor.The total signal intensity
(photon/sec/m2) was plotted against time after D-luciferin
injection to generate a time intensity curve from which
the maximal intensity and time to maximal intensity were
determined.
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Figure 1: Potential for missed injection when D-luciferin is administered IP. (a) OSC19-Luc tongue xenografts were established in 4 nude
mice, and BLI was performed after IP injection of D-luciferin. BLS intensity was evaluated for 1min at 7min after injection. Mouse no. 3
(∗) exhibits no BLS due to inadvertent intraintestinal injection. (b) Mouse no. 3 (∗) underwent a second IP administration of D-luciferin
and repeat BLI was performed. Mouse no. 3 (∗) exhibited the expected BLS after successful reinjection. (c) A single nude mouse bearing a
subcutaneous U87-Luc xenograft underwent BLI after deliberate intraintestinal injection of D-luciferin. BLS was collected continuously at
1min intervals as described inMethods. After 3 h, correct IP injection D-luciferin was performed, and BLS was collected as before.The graph
shows BLS intensity over time for the intestinal (INT) and IP injections.
2.4. Statistics. The peak signals were compared between SC
and IP injections using unpaired 2-tailed t-test. Comparisons
where 𝑃 < 0.05 were considered statistically significant.
3. Result and Discussion
3.1. Limitations of IP Injection. Theevolution of BLI of human
xenografts in immunocompromised mice has been driven
by the predominant use of this animal model in cancer
biology research. Although most researchers use IP injection
to administer D-luciferin for BLI, it may sometimes result
in accidental intestinal injection and consequent lack of BLS
due to decreased substrate availability at the tumor site.
Figure 1 demonstrates the risk ofmissed injectionwhen using
the IP technique. BLI was performed after IP injection of
D-luciferin of 4 nude mice bearing OSC19-Luc orthotopic
tongue xenografts. After IP injection of all mice, mouse no.
3 appeared to have no tumor (Figure 1(a)). When all mice
were properly reinjected with the substrate, accurate BLI
was obtained demonstrating a tongue tumor in mouse no.
3 comparable to the other mice in the group (Figure 1(b)).
The absence of an apparent tumor in mouse no. 3 after
the initial IP injection was presumably due to inadvertent
intraintestinal injection. The rate of IP injection failure has
been reported as 3–10% [14]; if not detected, this error
can have a substantial impact on the imaging data and its
interpretation. If the error is perceived, performing a second
injection will create a lag time that, for applications where a
high degree of precision is required, may result in an unac-
ceptable delay. Figure 1(c) shows the kinetics of the BLS in a
singlemouse bearing a subcutaneousU87-Luc xenograft after
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an intentional intraintestinal injection of D-luciferin com-
pared to the correct IP injection. The tumor produced only
minimal BLS intensity after the intraintestinal injection. After
a proper IP injection, the BLS signal exhibited the anticipated
intensity and showed appropriate time-dependent kinetics.
Another limitation to IP injection technique is the
obligatory 3–5min delay after injection for the induction of
inhalational anesthesia before BLI can be performed. The
detection of the very early signal could be lost and, if there
is a greater delay in the induction of anesthesia, the signal
could be weak or undetectable. In the process of quantitative
analysis of the intensity of the luminescence, the time of the
signal detection after substrate injection represents a crucial
factor despite the common use of a predetermined time point
to evaluate signal intensity [22]. SC injection is technically
simpler than IP and can be performed immediately after the
induction of anesthesia with more rapid injection of multiple
animals, thus ensuring that the initial luminescence will be
detected, that the peak signal will not be missed, and that
the peak signal will occur simultaneously in all animals.
With SC injection, delivery of the full dose of substrate is
ensured, reducing the risk that signal variation is due to
injection technique; it can be difficult to determine if a weak
signal results from inadequate injection or smaller tumor size,
particularly for orthotopic tumors that are not easily palpable.
3.2. Kinetics of BLS Intensity after SC versus IP Injection. The
kinetics of BLS intensity were compared in mice bearing sub-
cutaneous U87-Luc xenograft tumors after SC or IP injection
of D-luciferin (Figure 2). As described above, there is a 5min
delay in obtaining images for the animals that underwent IP
injection due to performing the injection prior to inducing
general anesthesia. The peak BLS after IP injection was
observed at 8min (range 5–8min); after SC injection the peak
luminescence was at 6min (range 5–9min). After 30min,
the signals for both injection techniques had fallen by more
than 50%. The signals were undetectable after 60min (data
not shown), indicating complete metabolism of the substrate.
With IP injection, luminescent intensity peaked earlier and
began to decrease sooner; after SC injection, maximal signal
was lower and occurred slightly later, but was sustainedmuch
longer at the peak level (approximately 10min).
3.3. Utility of SC Injection at Disparate Anatomic Sites. To
evaluate the relative signal quality resulting from SC versus
IP injection at different anatomic sites, a series of xenograft
models were tested (Figure 3). Multiple mice bearing sub-
cutaneous, intracranial, tongue, and pulmonary xenografts
were injected with D-luciferin via the SC or IP route, and
the BLS (photon/sec/m2) was measured 7min after injection
(1min collection; images in Figures 3(a)–3(d)). For each
model, the average BLS intensity was determined for SC and
IP injection after 3 distinct imaging sessions. BLS intensity
was similar in SC and IP injections in all models, with no
significant differences noted (graphs in Figures 3(a)–3(d)).
This demonstrates that, compared to IP injection, the SC
route of administration results in similar delivery of D-
luciferin to the target tissue for all anatomic sites tested.
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Figure 2: Time-intensity curves in various xenograft models. Five
nude mice bearing U87-Luc bilateral subcutaneous thigh xenograft
tumors underwent BLI after SC or IP injection. BLS was quantified
every min for 30min. The graph shows average BLS ± SEM. This
study was performed 3 times with similar results.
3.4. SC Injection Does Not Result in Preferential Biolumines-
cence. A simultaneous subcutaneous and intracranial tumor
model was used to determine whether SC injection causes
preferential bioluminescence (Figure 4(a)). The BLS emitted
from equal size bilateral subcutaneous thigh tumors and
an intracranial tumor after SC injection of D-luciferin was
plotted against time (Figure 4(b)). The first luminescent
signals emitted from the thigh and intracranial tumors were
simultaneously detected within the first min after SC injec-
tion, and signals from both sites achieved maximal intensity
at 10min. These data confirm that the anatomic location of
the tumor does not change the kinetics of luminescence after
SC substrate injection. Although D-luciferin has to traverse
the blood-brain barrier before it reaches the intracranial
tumor [23], simultaneous luminescence from intracranial
and thigh xenografts was observed after SC injection. These
data are in agreement with Inoue et al. who studied BLI
after SC injection of D-luciferin in animals having intra-
and extraperitoneal cavity tumors [24]. It should be noted
that, if there is concern regarding the timing of luminescence
in a multilocation tumor model, D-luciferin supplied via
intravenous injection could be used to verify the validity of
the SC injection approach [25].
3.5. BLI after SC Injection Reflects Tumor Growth. The
impact of tumor growth on the time course of luminescence
after SC injection was also evaluated. Seven days after
implantation, nude mice with U87-Luc subcutaneous thigh
xenograft tumors underwent BLI after SC injection with D-
luciferin. BLS was acquired every min for 30min starting
immediately after injection. The procedure was repeated on
postimplantation days 7, 10, and 14. The time to peak signal
intensity was consistent after 7, 10, and 14 days of xenograft
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Figure 3: BLI after SC versus IP injection at different anatomic sites. Nude mice bearing (a) U87-Luc bilateral subcutaneous thigh xenografts
(5 mice), (b) GBM12-Luc intracranial brain xenografts (3 mice), (c) OSC19-Luc tongue xenografts (5 mice), or (d) A549-Luc pulmonary
xenografts (2 mice) were imaged at 7min after SC injection and 7min after IP injection after an intervening washout period. Shown are
representative images after SC (right mouse) or IP (left mouse) injection of D-luciferin. For each anatomic site, the graph shows the average
BLS intensity (photon/sec/m2/1min) for IP and SC injection ± SEM after 3 distinct imaging sessions. No statistically significant differences
were noted.
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Figure 4: BLI ofmultisite xenograftmodel after SC injection. (a)A single nudemouse bearing bilateralU87-Luc subcutaneous thigh xenograft
tumors and, a simultaneous GBM12-Luc intracranial xenograft tumor was imaged 10min after SC injection of D-luciferin. (b) The BLS of
each tumor (1min collection) was plotted over time.
tumor growth (Figure 5). The peak signal intensity increased
as the experiment progressed, confirming the correlation of
signal intensity with tumor growth, as has been previously
reported [5, 18, 21]. The reproducibility of SC injection
appeared to be comparable to or better than IP injection. It
should be emphasized that in most BLI studies, to shorten
the imaging time, image acquisition is usually obtained at
a single, predetermined time point. Using the SC injection
approach, the time to the maximal BLS in each sequential
imaging pattern did not differ substantially from the mean
peak time; thus the assessment of tumor burden by single-
point imaging at the mean peak time could be expected to
yield similar results to previous studies using IP injection
[14, 26, 27].
The data obtained in this study are consistent with
previous findings by Inoue et al., but in ours we have
additionally tested the application of the SC injectionmethod
in a variety of tumor models involving disparate anatomic
sites and also in a simultaneous multisite tumor model. The
present study also addresses the impact of tumor growth on
bioluminescence after SC injection. The kinetics of signal
intensity and the relationship between the peak signal and the
time after cell implantation demonstrate that the BLS after SC
injection is correlated with tumor growth and that the signal
kinetics remains unchanged as the tumor enlarges.
4. Conclusion
SC injection of D-luciferin is a convenient and effective
alternative to IP injection for BLI of xenografts in nude
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Figure 5: BLS intensity after SC injection correlates with tumor
growth over time. Five nude mice bearing U87-Luc bilateral sub-
cutaneous thigh xenografts underwent BLI after SC injection of D-
luciferin on days 7, 10, and 14 after implantation. BLS was collected
every minute for 30min, and signal intensities were plotted against
time on each day the 5 mice were assessed. Error bars indicate SEM.
mice. SC injection is free from risk of injection failure
and offers consistent results for BLI of various luciferase-
expressing tissues. SC injectionmay be a preferable approach,
particularly for tumors with weaker signals and/or when
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greater precision is required, or when consistently effective
IP injection is more difficult.
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